Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis

Acta Neurologica Scandinavica

Volumn 130, Issue 2, 2014, Pages 90-96

  Torring C ^a,b   Andreasen, C ^b   Gehr, N ^b   Bjerg, L ^b   Petersen, T ^a   Hollsberg P ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Epstein Barr virus; Lymphoblastoid cell lines; Relapsing remitting multiple sclerosis; Switched memory B cells

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CORTICOSTEROID; LEUKOSIALIN;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCIDENCE; LEUKOCYTE COUNT; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE TRANSFORMATION; MALE; MEMORY CELL; MONOCYTE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS LOAD; BLOOD; CASE CONTROL STUDY; DENMARK; EPIDEMIOLOGY; EPSTEIN-BARR VIRUS INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; VIROLOGY;

ADULT; B-LYMPHOCYTES; CASE-CONTROL STUDIES; DENMARK; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS;

EID: 84904646539     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12249     Document Type: Article

References (23)

1. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.
2. Toussirot E, Roudier J. Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008;22:883-96.
3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99.
4. Haahr S, Plesner AM, Vestergaard BF, Hollsberg P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand 2004;109:270-5.
5. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499-503.
6. Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006;67:2063-5.
7. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78:823-32.
8. Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-912.
9. Serafini B, Severa M, Columba-Cabezas S et al. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 2010;69:677-93.
10. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 2011;134:2772-86.
11. Pender MP, Csurhes PA, Lenarczyk A, Pfluger CM, Burrows SR. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:498-505.
12. Hollsberg P, Hansen HJ, Haahr S. Altered CD8 + T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 2003;132:137-43.
13. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
15. Fraser KB, Haire M, Millar JH, McCrea S. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet 1979;2:175-6.
16. Munch M, Moller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein-Barr virus. Mult Scler 1995;1:78-81.
17. Frisan T, Levitsky V, Masucci M. Generation of lymphoblastoid cell lines (LCLs). Methods Mol Biol 2001;174:125-7.
18. Torring C, Petersen CC, Bjerg L, Kofod-Olsen E, Petersen T, Hollsberg P. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2013;262:92-9.
19. Griffin DO, Rothstein TL. Human b1 cell frequency: isolation and analysis of human b1 cells. Front Immunol 2012;3:122.
20. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995;80:593-601.
21. Lucas RM, Ponsonby AL, Dear K et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011;77:371-9.
22. Lindsey JW, Hatfield LM, Crawford MP, Patel S. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult Scler 2009;15:153-8.
23. Hon GM, Hassan MS, van Rensburg SJ, Erasmus RT, Matsha TE. Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis. Metab Brain Dis 2012;27:311-8.